Anlotinib
- Generic Name
- Anlotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22FN3O3
- CAS Number
- 1058156-90-3
- Unique Ingredient Identifier
- GKF8S4C432
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Indication
用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。
用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2021-03-15
- Target Recruit Count
- 206
- Registration Number
- NCT04797806
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 40
- Registration Number
- NCT04777162
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib
- Conditions
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04770688
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Yong Chen
- Target Recruit Count
- 45
- Registration Number
- NCT04765228
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 52
- Registration Number
- NCT04764084
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Third Military Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT04731909
- Locations
- 🇨🇳
Daping Hospital, Third Military Medical University, Chongqing, Chongqing, China
Anlotinib Combined With STUPP for MGMT Nonmethylated Glioblastoma
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2021-01-26
- Target Recruit Count
- 33
- Registration Number
- NCT04725214
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Anlotinib to Malignant Brainstem Glioma
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT04668508
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 196
- Registration Number
- NCT04574284
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing, China
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- Xiaoxiang Chen
- Target Recruit Count
- 68
- Registration Number
- NCT04566952
- Locations
- 🇨🇳
JiangSu Cancer Hospital, Nanjing, Jangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.